Research programme: inflammation therapy - 7TM Pharma
Latest Information Update: 07 Jul 2010
Price :
$50 *
At a glance
- Originator 7TM Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 09 May 2006 Preclinical trials in Inflammation in Denmark (unspecified route)